In lung cancer, predictive biomarkers detected through ctDNA include EGFR mutations that guide targeted therapy selection, blood tumor mutational burden (bTMB), and mutational signatures that predict responsiveness to immunotherapy, as well as the detection of MRD following treatment, which serves as a predictor of disease recurrence and survival outcomes [49]. This evidence concerns the gene EGFR and lung cancer.